Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Robert H.I. Andtbacka"'
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Autor:
Howard L. Kaufman, Kevin S. Gorski, Mohammed M. Milhem, David R. Minor, Jeffrey Chou, Robert H.I. Andtbacka, Ai Li, Igor Puzanov, Michael Chastain, Omid Hamid, Abraham Antonio Anderson, Lisa Chen
Publikováno v:
J Clin Oncol
Purpose Combining immunotherapeutic agents with different mechanisms of action may enhance efficacy. We describe the safety and efficacy of talimogene laherparepvec (T-VEC; an oncolytic virus) in combination with ipilimumab (a cytotoxic T-lymphocyte
Autor:
Jon M. Richards, Mark Grose, Mark B. Faries, Robert H.I. Andtbacka, Brendan D. Curti, Darren R. Shafren, Greg Daniels, Sigrun Hallmeyer
Publikováno v:
Cancer Research. 77:CT114-CT114
Background: CAVATAKTM is a novel bio-selected oncolytic and immunotherapeutic strain of Coxsackievirus A21 (CVA21). In a phase 2 study, intratumoral (i.t.) CVA21 injection of advanced melanoma lesions resulted in increases in tumor immune-cell infilt
Autor:
Sanjiv S. Agarwala, John T. Vetto, Rogerio I. Neves, Robert H.I. Andtbacka, Matthew H. Taylor, Richard S. Ungerleider, Adil Daud, Merrick I. Ross, Maki Tanaka, Aislyn D. Boran, Hung T. Khong, Kenneth F. Grossmann
Publikováno v:
Journal of Clinical Oncology. 34:9543-9543
9543Background: HF10 is a replication-competent oncolytic virus derived from HSV-1. We report on preliminary safety data and antitumor activity of HF10 + ipilimumab (ipi) combination in an ongoing Phase 2 trial in melanoma. Methods: Key entry criteri